Recently added Catalysts

ACCG-2671

Phase 1

Obesity | Small molecule | Metabolic |Structure Therapeutics Inc.|Last Updated: Sep 11, 2026

Target and mechanism

Molecular targetamylin receptor

Target classReceptor

ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED

Total Trials1

Total Enrollment164

FDA Designations

No designations recorded

Clinical trial landscape

ACCG-2671 · 1 trial · 1 indication

Phase 1 1

NCT07815678First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671Obesity

RECRUITING164 Analytics

PHASE1RECRUITING

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

Obesity

NCT07815678164

Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with one or more adverse events (AEs) as assessed by CTCAE v5.0

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Number of participants with one or more serious adverse advents (SAEs) as assessed by CTCAE v5.0

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 24 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Number of participants with one or more treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0

Baseline to Day 21 (Part 2)

Change from baseline in systolic blood pressure

Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in diastolic blood pressure

Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in heart rate

Baseline to Day 15 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in ECG ventricular heart rate

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

Change from baseline in ECG PR interval

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

Change from baseline ECG QRS duration

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

Change from baseline in ECG QT Interval corrected using Fridericia's Formula (QTcF)

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); predose to Day 70 (Part 3)

Change from baseline in hemoglobin

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in hematocrit

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in thrombocyte count (platelet count)

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in white blood cell (WBC) count

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in prothrombin time

Baseline to day 17 (Part 1, Cohorts 1, 2, and 3); baseline to day 22 (Part 1, Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3)

Change from baseline in international normalized ratio (INR)

Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to day 22 (Part 1 Cohorts 4 and 5); baseline to day 21 (Part 2); baseline to day 112 (Part 3)

Change from baseline in activated partial thromboplastin time (aPTT)

Baseline to day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in fibrinogen activity

Baseline to Day 17 (Part 1, Cohorts 1, 2 and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in sodium

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in potassium

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in chloride

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in phosphate

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in calcium

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in glucose

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in amylase

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in lipase

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in magnesium

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in albumin

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in lactate dehydrogenase (LDH)

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in creatine kinase

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in creatinine

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in blood urea nitrogen

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in alanine aminotransferase (ALT)

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in total alkaline phosphatase

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in aspartate aminotransferase (AST)

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in gamma-glutamyl transferase (GGT)

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in total bilirubin

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in direct bilirubin

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in indirect bilirubin

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Number of participants with abnormal urinalysis parameters

Baseline to Day 17 (Part 1, Cohorts 1, 2, and 3); baseline to Day 22 (Part 1, Cohorts 4 and 5); baseline to Day 21 (Part 2); baseline to Day 112 (Part 3)

Change from baseline in urinalysis (Including pH, specific gravity, glucose, protein, ketones, blood, nitrites, urobilinogen, and leukocyte esterase)

Secondary Endpoints

Maximum observed plasma concentration (Cmax) of ACCG-2671

Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)

Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of ACCG-2671

Predose through Day 22 (Part 1); predose through Day 18 (Part 2)

Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) of ACCG-2671

Predose through Day 22 (Part 1); predose through Day 18 (Part 2); predose through Day 112 (Part 3)

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED

MaskingTRIPLE

ModelPARALLEL

PurposeTREATMENT

Treatment Arms

Arm	Type	Description
Part 1 (SAD)	EXPERIMENTAL	Ascending doses of ACCG-2671 administered orally in healthy participants
Placebo Part 1 (SAD)	PLACEBO_COMPARATOR	Administered orally in healthy participants
Part 2 (Food-effect)	EXPERIMENTAL	Single low dose of ACCG-2671 administered orally in healthy participants under fasted and fed state
ACCG-2671 Part 3 (MAD)	EXPERIMENTAL	Escalating doses of ACCG-2671 administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)
Placebo Part 3 (MAD)	PLACEBO_COMPARATOR	Placebo administered orally for 84 days in participants living with obesity (BMI≥30 kg/m2)

Interventions

Name	Type	Description
ACCG-2671	DRUG	Administered orally
Placebo	DRUG	Administered orally

Unlock Study Design Details

Eligibility Criteria

Age Range25 Years to 75 Years

SexALL

Healthy VolunteersYes

Study Sites6

Inclusion Criteria: * Signed informed consent * Men and women with the following at the time of Screening for Part 1 and 2: ≥25 years and ≤65 years of age and BMI ≥18.0 kg/m2 and \<30.0 kg/m2 * For Part 3, ≥25 years and ≤75 years of age and BMI ≥30.0 kg/m2 * For Part 3, receiving a stable dose of a...

Countries:United States

Unlock Eligibility Criteria

Competitive Landscape -Obesity 185 trials

Top 20 of 32 competitors

Company	Ticker	Trials	Lead Phase	Drugs
Amgen Inc.	AMGN	8	PHASE3	Maridebart cafraglutide
Eli Lilly and Company	LLY	37	PHASE3	Orforglipron
Novo Nordisk A/S Sponsored ADR Class B	NVO	45	PHASE3	Cagrilintide, Semaglutide
Rhythm Pharmaceuticals, Inc.	RYTM	6	PHASE3	Setmelanotide
Regeneron Pharmaceuticals, Inc.	REGN	3	PHASE3	Mibavademab
Pfizer Inc.	PFE	1	PHASE3	PF-08653944
Vanda Pharmaceuticals Inc.	VNDA	1	PHASE3	Tradipitant
Kailera Therapeutics, Inc.	KLRA	4	PHASE3	Ribupatide
AstraZeneca PLC	AZN	3	PHASE2	AZD6234
Pfizer	MTSR	3	PHASE3	MET097
Structure Therapeutics, Inc. Sponsored ADR	GPCR	2	PHASE2	Undisclosed
Biohaven Ltd.	BHVN	1	PHASE2	Taldefgrobep Alfa
Skye Bioscience, Inc.	SKYE	1	PHASE2	Nimacimab, semaglutide
Palatin Technologies, Inc.	PTN	1	PHASE2	bremelanotide, tirzepatide
Veru Inc	VERU	1	PHASE2	Enobosarm, Semaglutide weekly
Arrowhead Pharmaceuticals, Inc.	ARWR	2	PHASE1	ARO-INHBE, Tirzepatide
Alnylam Pharmaceuticals, Inc	ALNY	1	PHASE1	ALN-2232, Tirzepatide
Gilead Sciences, Inc.	GILD	1	PHASE1	GS-4571, Omeprazole
AbbVie, Inc.	ABBV	1	PHASE1	ABBV-295
MBX Biosciences, Inc.	MBX	1	PHASE1	MBX 4291

Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWSep 11, 2026NCT07815678NEW_TRIAL: changed

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

News

Blogs

Modality Leaderboard

Disease Map

API

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

ACCG-2671

Target and mechanism

Success Probability

Market & Valuation

Trial Design

FDA Designations

Clinical trial landscape

Study Endpoints

Primary Endpoints

Secondary Endpoints

Study Design & Arms

Treatment Arms

Interventions

Eligibility Criteria

Competitive Landscape -Obesity 185 trials

Recent Changes (Last 90 Days)

Other drugs targeting amylin receptor